Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allegra, Zyrtec Will Not Follow Claritin OTC In Near Future, Execs State

This article was originally published in The Tan Sheet

Executive Summary

Aventis and Pfizer have no plans to switch their low- and non-sedating antihistamines OTC in the wake of Schering-Plough's decision to pursue FDA approval of nonprescription Claritin, company execs said at the SG Cowen healthcare conference in Boston March 13

You may also be interested in...



OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough

Schering-Plough does not expect to receive three years of Hatch/Waxman exclusivity for its supplemental NDAs for OTC Claritin (loratadine)

Claritin Patent Infringement Suit Brings Industry Into OTC Antihistamine Fray

Schering-Plough's lawsuits against McNeil Consumer Healthcare and Whitehall-Robins could at least temporarily relieve FDA of having to make a highly charged public policy decision on whether to advocate a forced switch of second-generation antihistamines

OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan

Nonsedating antihistamines classified as prescription drugs would be more appropriately sold as OTCs, Blue Cross of California Pharmacy VP Rob Seidman maintains in Jan. 12 letters sent to marketers of the drugs.

Related Content

Topics

UsernamePublicRestriction

Register

PS093743

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel